Global Anti-Infectives Market Trends, Size, Forecast: By Drug Type: Antibiotics, Antifungal, Antiviral, Others; By Indication: HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, Others indication; By Route of Administration: Topical, Oral, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Infectious Disease Overview
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Infectious Disease Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Infectious Disease Epidemiology (2016-2031)
    5.3    Europe Infectious Disease Epidemiology (2016-2031)
    5.4    Asia-Pacific Infectious Disease Epidemiology (2016-2031)
    5.5    Latin America Infectious Disease Epidemiology (2016-2031)
    5.6    Middle East & Africa Infectious Disease Epidemiology (2016-2031)
6    Global Anti-Infective Market Overview 
    6.1    Global Anti-Infective Market Historical Value (2017-2023) 
    6.2    Global Anti-Infective Market Forecast Value (2024-2032)
7    Global Anti-Infective Market Landscape
    7.1    Anti-Infective: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Anti-Infective: Product Landscape
        7.2.1    Analysis by Drug Type
        7.2.2    Analysis by Indication
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by Distribution Channel
8    Anti-Infective Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Anti-Infective Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Anti-Infective Market Segmentation
    11.1    Global Anti-Infective Market by Drug Type
        11.1.1    Market Overview
        11.1.2    Antibiotics
        11.1.3    Antifungal
        11.1.4    Antiviral
        11.1.5    Others
    11.2    Global Anti-Infective Market by Indication
        11.2.1    Market Overview
        11.2.2    HIV Infection
        11.2.3    Pneumonia
        11.2.4    Respiratory Virus Infection
        11.2.5    Sepsis
        11.2.6    Tuberculosis
        11.2.7    Others indication
    11.3    Global Anti-Infective Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Topical
        11.3.3    Oral
        11.3.4    Intravenous (IV)
        11.3.5    Others
    11.4    Global Anti-Infective Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online Pharmacy
        11.4.5    Others
    11.5    Global Anti-Infective Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Anti-Infective Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Anti-Infective Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Anti-Infective Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Anti-Infective Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Anti-Infective Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Gilead Sciences, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Sandoz International GmbH
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Pfizer Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    GlaxoSmithKline plc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Abbott
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Alcon Pharmaceuticals Ltd.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Astellas Pharma Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Astrazeneca plc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Bayer Healthcare AG
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Alkem Labs
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Anti-Infective - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)
    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.